65,437 trials
Healthy Young Adults
Primary: Energy Expenditure — 0.9; 5.0; 3.9; 3.8 METs
Hyperhidrosis
Primary: Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase — 96.2; 45.9 percentage of participants — p=<0.001
Cerebrovascular Disease
Primary: Blood Pressure and Heart Rates;
Healthy
Primary: Linagliptin: Maximum Measured Concentration (Cmax) — 5.36; 5.39 nmol/L
Head Lice
Primary: Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points — 0.00000; 0.02528; 0.08192; 0.20075 ng/mL
Open Angle Glaucoma
Primary: Postoperative Intraocular Pressure Change — -11.3; -11.6 mm Hg — p=0.95
Telemedicine Evaluation vs Telephone Evaluation
Primary: Functional Outcome (mRS(0-1)) at 6 Months After Index Event. The mRS is the Modified Rankin Scale That Measures Patient's Functional Level of Activity. The Scale is a 6…
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 2; 3; 1; 0 Participants
Cataract
Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03
Pleural Effusion Associated With Pulmonary Infection · Bacterial Pleural Effusion Other Than Tuberculosis
Primary: No Surgical Intervention — 66; 6 participants — p=<0.001
Cancer
Primary: Plasma Pazopanib Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC[0-24]) of Pazopanib Alone and of Pazopanib in Combination With…
HIV Infections
Primary: Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml — -3.16; -3.31; -3.26; -3.20 log10 HIV-1 RNA — p=0.26
Triple Negative Locally Advanced Non-resectable Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) — 30.0; 35.9 percentage of participants
Glaucoma · Ocular Hypertension
Primary: Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT) — 0.8; 1.1 seconds
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score — -9.1; -10.2 Units on a scale